CSL strikes deal worth up to $1.6 billion with Swiss firm Alentis for rare kidney and liver disease drug

CSL agreed to pay as much as $1.6 billion to Swiss firm Alentis to jointly develop and sell an experimental treatment for rare kidney and liver diseases, expanding the Australian biotech company's push into kidney medicine. Reuters reported the deal.

Detected & updated continuously · Source: Nebula